New trial data show aflibercept 8 mg and faricimab extend dosing to 16–20 weeks in AMD, DME, RVO while maintaining safety.

Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

The largest global, prospective, noninterventional study of faricimab demonstrated “robust, rapid” anatomical improvements in patients with diabetic macular edema, according to a speaker. The VOYAGER ...

Incorporation of an artificial intelligence-based-optical coherence tomography (AI-OCT) system as a secondary screening tool ...

The purpose of this study is to investigate whether history of silicone oil tamponade may predispose to the development of cystoid macular edema (CMO) following uneventful post-vitrectomy cataract ...

The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

We included RVO patients who were treated with anti-VEGF (ranibizumab, aflibercept or conbercept) or dexamethasone (DEX) implants (Ozurdex) from November 2022 to December 2023 for ME secondary to RVO ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

For patients with diabetic macular edema (DME), intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection ...

Lead program, MMT-205, licensed from MabTics Co., Ltd / Curacle Co., Ltd. is a potential best-in-class bispecific antibody which activates Tie2 ...